Pothen, A. | Search bioRxiv

bioRxiv2025

An optimal transport-based low-dimensional visualization framework for high-parameter flow cytometry

Conventional data visualization techniques in single-cell analysis (such as two-dimensional dot plots, SPADE, PCA, t-SNE, or UMAP) often fall short in providing an intuitive understanding of high-parameter flow cytometry data. These methods tend to oversimplify complex biological relationships, lack biologically meaningful interpretations, and offer no principled framework for downstream quantitative analysis. To address these limitations, we present a graph-based visualization framework grounded in optimal transport theory. In this framework, cell populations are defined by their marker-expression profiles, and inter-population similarity is quantified using an efficiently computable optimal transport formulation known as the Sinkhorn distance. Our approach produces biologically consistent two-dimensional graph layouts using a phenotypeaware Hamming distance. Structural differences between sample graphs are characterized through a customized graph-edit distance that captures changes in population size, marker expression, and relationships between populations. We demonstrate our methods on two flow cytometry datasets: one from a clinical trial of dendritic cell-based immunotherapy in malignant peritoneal mesothelioma, involving 14 patients sampled at three time points with 14-color panels, and another from FlowCAP-II, which involved 43 acute myeloid leukemia patient samples analyzed with 7-color panels. Our framework produces robust, quantitative visual summaries of cell populations and supports statistical analysis based on graph edit distances, thereby offering new insights into disease progression and treatment response. Ultimately, our method bridges the gap between flow cytometry data visualization and biological interpretation.

bioinformatics↗

bioRxiv2024

DigiLoCS: A Leap Forward in Predictive Organ-on-Chip Simulations

Digital twins, driven by data and mathematical modelling, have emerged as powerful tools for simulating complex biological systems. In this work, we focus on modelling the clearance on a liver-on-chip as a digital twin that closely mimics the clearance functionality of the human liver. Our approach involves the creation of a compartmental physiological model of the liver using ordinary differential equations (ODEs) to estimate pharmacokinetic (PK) parameters related to on-chip liver clearance. The objectives of this study were twofold: first, to predict human clearance values, and second, to propose a framework for bridging the gap between in vitro findings and their clinical relevance. The methodology integrated quantitative Organ-on-Chip (OoC) and cell-based assay analyses of drug depletion kinetics and is further enhanced by incorporating an OoC-digital twin model to simulate drug depletion kinetics in humans. The in vitro liver clearance for 32 drugs was predicted using a digital-twin model of the liver-on-chip and in vitro to in vivo extrapolation (IVIVE) was assessed using time series PK data. Three ODEs in the model define the drug concentrations in media, interstitium and intracellular compartments based on biological, hardware, and physicochemical information. A key issue in determining liver clearance appears to be the insufficient drug concentration within the intracellular compartment. The digital twin establishes a connection between the hardware chip structure and an advanced mapping of the underlying biology, specifically focusing on the intracellular compartment. Our modelling offers the following benefits: i) better prediction of intrinsic liver clearance of drugs compared to the state-of-the-art model and ii) explainability of behaviour based on physiological parameters. Finally, we illustrate the clinical significance of this approach by applying the findings to humans, utilising propranolol as a proof-of-concept example. This study stands out as the biggest cross-organ-on-chip platform investigation to date, systematically analysing and predicting human clearance values using data obtained from various in vitro liver-on-chip systems. Author summaryAccurate prediction of in vivo clearance from in vitro data is important as inadequate understanding of the clearance of a compound can lead to unexpected and undesirable outcomes in clinical trials, ranging from underdosing to toxicity. Physiologically based pharmacokinetic (PBPK) model estimation of liver clearance is explored. The aim is to develop digital twins capable of determining better predictions of clinical outcomes, ultimately reducing the time, cost, and patient burden associated with drug development. Various hepatic in vitro systems are compared and their effectiveness for predicting human clearance is investigated. The developed tool, DigiLoCs, focuses explicitly on accurately describing complex biological processes within liver-chip systems. ODE-constrained optimisation is applied to estimate the clearance of compounds. DigiLoCs enable differentiation between active biological processes (metabolism) and passive processes (permeability and partitioning) by incorporating detailed information on compound-specific characteristics and hardware-specific data. These findings signify a significant stride towards more accurate and efficient drug development methodologies.

pharmacology and toxicology↗